SteelPeak Wealth LLC Cuts Stock Holdings in iShares Biotechnology ETF $IBB

SteelPeak Wealth LLC cut its stake in iShares Biotechnology ETF (NASDAQ:IBBFree Report) by 2.1% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,977 shares of the financial services provider’s stock after selling 129 shares during the period. SteelPeak Wealth LLC’s holdings in iShares Biotechnology ETF were worth $756,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Citigroup Inc. increased its holdings in iShares Biotechnology ETF by 88.5% in the first quarter. Citigroup Inc. now owns 3,208,144 shares of the financial services provider’s stock valued at $410,322,000 after buying an additional 1,505,976 shares in the last quarter. Commonwealth Equity Services LLC increased its holdings in iShares Biotechnology ETF by 12.0% in the first quarter. Commonwealth Equity Services LLC now owns 194,516 shares of the financial services provider’s stock valued at $24,879,000 after buying an additional 20,915 shares in the last quarter. Jones Financial Companies Lllp increased its holdings in iShares Biotechnology ETF by 763.3% in the first quarter. Jones Financial Companies Lllp now owns 151,265 shares of the financial services provider’s stock valued at $19,347,000 after buying an additional 133,744 shares in the last quarter. Generali Investments CEE investicni spolecnost a.s. increased its holdings in iShares Biotechnology ETF by 35.0% in the second quarter. Generali Investments CEE investicni spolecnost a.s. now owns 116,115 shares of the financial services provider’s stock valued at $14,690,000 after buying an additional 30,115 shares in the last quarter. Finally, MAI Capital Management increased its holdings in iShares Biotechnology ETF by 4.2% in the first quarter. MAI Capital Management now owns 98,158 shares of the financial services provider’s stock valued at $12,554,000 after buying an additional 3,923 shares in the last quarter. 62.45% of the stock is owned by hedge funds and other institutional investors.

iShares Biotechnology ETF Stock Up 1.0%

Shares of iShares Biotechnology ETF stock opened at $151.99 on Thursday. iShares Biotechnology ETF has a 12-month low of $107.43 and a 12-month high of $153.01. The company has a 50-day moving average of $140.21 and a two-hundred day moving average of $130.36.

iShares Biotechnology ETF Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, September 19th. Stockholders of record on Tuesday, September 16th were given a $0.0828 dividend. The ex-dividend date was Tuesday, September 16th. This represents a $0.33 annualized dividend and a dividend yield of 0.2%.

iShares Biotechnology ETF Profile

(Free Report)

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Further Reading

Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBBFree Report).

Institutional Ownership by Quarter for iShares Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.